The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | The role of CAR-T therapy in primary and secondary CNS lymphoma
Muhammad Husnain, MD, University of Arizona, Arizona Cancer Center, Tucson, AZ, discusses the role of CAR-T therapy in primary and secondary central nervous system (CNS) lymphoma. These patients have dismal outcomes after they relapse following initial therapy. In addition, they have been excluded from clinical trials evaluating CAR-T therapies in non-Hodgkin lymphoma (NHL). A systemic review including 17 studies evaluating CAR-T therapy in relapsed/refractory (R/R) primary and secondary CNS lymphoma showed that the efficacy and toxicity profile of CAR-T therapy in these patients was comparable to that of patients who do not have CNS involvement, suggesting that patients with CNS lymphoma should be included in future clinical trials for CAR-T therapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
